Moving Against the Tide: Special Research on Jack in the Box, Boston Scientific, Potbelly, Chemed, and Cinemark
NEW YORK, February 19, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Jack in the Box (NASDAQ: JACK), Boston Scientific (NYSE: BSX), Potbelly (NASDAQ: PBPB), Chemed (NYSE: CHE), and Cinemark (NYSE: CNK). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
JACK Research Report: ( http://get.analystsreview.com/pdf/?c=Jack%20in%20the%20Box&d=19-Feb-2015&s=JACK ),
BSX Research Report: ( http://get.analystsreview.com/pdf/?c=Boston%20Scientific&d=19-Feb-2015&s=BSX ),
PBPB Research Report: ( http://get.analystsreview.com/pdf/?c=Potbelly&d=19-Feb-2015&s=PBPB ),
CHE Research Report: ( http://get.analystsreview.com/pdf/?c=Chemed&d=19-Feb-2015&s=CHE ),
CNK Research Report: ( http://get.analystsreview.com/pdf/?c=Cinemark&d=19-Feb-2015&s=CNK ).
============
--
Analyst Update: Better than Expected Quarterly Results and Litigation Settlement
Reviewed by: Rohit Tuli, CFA®
The US stock markets mostly closed lower on Wednesday despite progress in Greece negotiations and dovish Fed minutes. Dow Jones Industrial Average closed down 17.85 points, or 0.10%, at 18,029.85; S&P 500 closed down 0.68 points, or 0.03%, at 2,099.66; Nasdaq closed up 7.10 points, or 0.14%, at 4,906.36. European stocks ended mostly higher and rose to seven-year high amid Greek deal prospects, as Greece is expected to submit a loan request on Thursday to extend a loan agreement for up to six months. The FTSEuroFirst 300 index rose 0.7% to a fresh seven-year high of 1,515.90. On the other hand, most Asian stocks advanced on Wednesday due to investor optimism ahead of a European Central Bank meeting on bailout conditions for Greece, though many markets of the region were shut for the Lunar New Year.
Jack in the Box Inc. (Jack in the Box) hit a new 52-week high on Wednesday, February 18, following a stronger than expected earnings report for first quarter of fiscal 2015 released on the previous day. Shares of the San Diego-based restaurant company rose 7.42% on the last close. To know how the operator of Jack in the Box® and Qdoba Mexican Grill® restaurants fared during the quarter and its guidance for the second quarter 2015, visit our research report on Jack in the Box.
Shares of Boston Scientific Corporation (Boston Scientific) gained 12.40% to end Wednesday's trading at $16.68 following reports that the Company has agreed to pay a total of $600 million to Johnson & Johnson, in settlement of the breach of merger agreement lawsuit brought by Johnson & Johnson against Guidant Corporation. Know more about the Boston Scientific's litigation settlement in our research report.
Shares in Potbelly Corp. (Potbelly) rallied 16.62% on February 18 to close at $16.56 following robust fourth quarter fiscal 2014 results. Potbelly reported net income of $0.7 million, compared to a net loss of $3.7 million during Q4 FY 2013. Adjusted EPS of $0.06 for the quarter exceeded the Zacks consensus estimate of $0.04. To know more about financial performance of the Company, please read our research report on Potbelly.
The Cincinnati-based company Chemed Corporation reported financial results for its fourth quarter ended December 31, 2014, after market hours on February 17. The shares rose 6.95% on the following day to $115.43, on an earnings surprise of $0.11 per share. According to consensus estimates available at Streetinsider.com, analysts had expected the Company to post an EPS of $1.69 per share. The Company however surpassed this expectation and reported a 24.1% YoY growth in its Q4'14 adjusted diluted EPS of $1.80. To know more about the robust performance of the Company, please read our research report on Chemed Corporation.
Cinemark Holdings, Inc. (Cinemark) shares gained 5.42% and achieved a new 52-week high of $41.91 before closing the session at $41.20 on February 18, 2015, as the Company's Q4 2014 earnings results beat market expectations. Zacks Investment Research data had suggested an EPS of $0.33, whereas the Company posted an EPS of $0.41 for the quarter. Cinemark's revenues for the quarter increased 1.2% YoY to $659.9 million, while adjusted EBITDA increased 11.4% YoY to $156.9 million. Find more about Cinemark's financial performance in our research report.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article